CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni Sells 4,293 Shares

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 4,293 shares of the firm’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $198,680.04. Following the completion of the sale, the chief executive officer now owns 226,540 shares of the company’s stock, valued at $10,484,271.20. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

CRISPR Therapeutics Stock Performance

Shares of CRSP opened at $48.29 on Friday. The firm has a market cap of $4.10 billion, a P/E ratio of -17.75 and a beta of 1.68. CRISPR Therapeutics AG has a twelve month low of $37.55 and a twelve month high of $91.10. The firm’s 50 day moving average price is $47.15 and its two-hundred day moving average price is $53.56.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, August 5th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.43) by ($0.06). The business had revenue of $0.52 million during the quarter, compared to analysts’ expectations of $12.31 million. CRISPR Therapeutics’s revenue for the quarter was down 99.3% on a year-over-year basis. During the same quarter last year, the company earned ($0.98) earnings per share. On average, sell-side analysts anticipate that CRISPR Therapeutics AG will post -5.6 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of large investors have recently bought and sold shares of CRSP. Integrated Advisors Network LLC lifted its position in shares of CRISPR Therapeutics by 6.9% in the fourth quarter. Integrated Advisors Network LLC now owns 7,703 shares of the company’s stock worth $482,000 after purchasing an additional 500 shares in the last quarter. Greenwood Capital Associates LLC lifted its position in CRISPR Therapeutics by 23.8% during the 4th quarter. Greenwood Capital Associates LLC now owns 6,801 shares of the company’s stock worth $426,000 after buying an additional 1,306 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of CRISPR Therapeutics by 3.4% during the 4th quarter. Vanguard Group Inc. now owns 1,590,651 shares of the company’s stock worth $99,575,000 after buying an additional 51,926 shares during the last quarter. HighPoint Advisor Group LLC bought a new position in shares of CRISPR Therapeutics in the 4th quarter valued at about $270,000. Finally, Nomura Holdings Inc. acquired a new stake in shares of CRISPR Therapeutics in the fourth quarter valued at about $433,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

Wall Street Analysts Forecast Growth

CRSP has been the subject of a number of research reports. StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a report on Friday, August 16th. Chardan Capital dropped their target price on CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. Barclays decreased their price target on CRISPR Therapeutics from $67.00 to $59.00 and set an “equal weight” rating on the stock in a report on Tuesday, August 6th. Truist Financial dropped their price objective on CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a report on Monday, August 12th. Finally, Needham & Company LLC reduced their target price on shares of CRISPR Therapeutics from $88.00 to $84.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, CRISPR Therapeutics currently has an average rating of “Hold” and a consensus target price of $75.19.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.